SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will assess the impact of bone marker feedback, using blood sampling and
communication of results at week 5, on persistence to monthly Bonviva (150mg po) in women
with post-menopausal osteoporosis. The study will also assess safety, quality of life and
patient satisfaction. All patients will receive Bonviva 150mg po monthly, and will be
randomized into the bio-feedback or no bio-feedback study arms. The anticipated time on study
treatment is 3-12 months, and the target sample size is 500+ individuals.